Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IVA NASDAQ:MCRB NASDAQ:OLMA NYSE:PRME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIVAInventiva$5.26-1.2%$4.23$1.53▼$6.50$502.69M0.6924,138 shs22,832 shsMCRBSeres Therapeutics$17.31-0.5%$16.04$6.53▼$24.67$151.46M0.15115,691 shs58,126 shsOLMAOlema Pharmaceuticals$7.86-0.4%$5.61$2.86▼$13.93$539.43M1.92900,222 shs253,028 shsPRMEPrime Medicine$4.82+3.3%$3.89$1.11▼$5.17$643.94M2.382.56 million shs2.52 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIVAInventiva+0.19%-0.75%+22.02%+59.71%+140.72%MCRBSeres Therapeutics+10.90%-6.70%+4.25%+125.10%-14.71%OLMAOlema Pharmaceuticals-1.38%+6.05%+43.19%+92.44%-35.43%PRMEPrime Medicine+16.46%+13.35%+30.81%+159.44%+24.87%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIVAInventiva$5.26-1.2%$4.23$1.53▼$6.50$502.69M0.6924,138 shs22,832 shsMCRBSeres Therapeutics$17.31-0.5%$16.04$6.53▼$24.67$151.46M0.15115,691 shs58,126 shsOLMAOlema Pharmaceuticals$7.86-0.4%$5.61$2.86▼$13.93$539.43M1.92900,222 shs253,028 shsPRMEPrime Medicine$4.82+3.3%$3.89$1.11▼$5.17$643.94M2.382.56 million shs2.52 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIVAInventiva+0.19%-0.75%+22.02%+59.71%+140.72%MCRBSeres Therapeutics+10.90%-6.70%+4.25%+125.10%-14.71%OLMAOlema Pharmaceuticals-1.38%+6.05%+43.19%+92.44%-35.43%PRMEPrime Medicine+16.46%+13.35%+30.81%+159.44%+24.87%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIVAInventiva 2.83Moderate Buy$14.83182.27% UpsideMCRBSeres Therapeutics 1.75Reduce$73.67325.57% UpsideOLMAOlema Pharmaceuticals 2.83Moderate Buy$24.00205.34% UpsidePRMEPrime Medicine 2.75Moderate Buy$8.9284.84% UpsideCurrent Analyst Ratings BreakdownLatest MCRB, PRME, IVA, and OLMA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/9/2025OLMAOlema PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold9/3/2025IVAInventivaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$20.009/3/2025OLMAOlema PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$22.009/2/2025IVAInventivaGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.00 ➝ $13.008/27/2025IVAInventivaPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$26.008/27/2025IVAInventivaPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$26.008/14/2025OLMAOlema PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$28.00 ➝ $29.008/12/2025OLMAOlema PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$20.00 ➝ $21.008/11/2025OLMAOlema PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell8/8/2025PRMEPrime MedicineChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$12.00 ➝ $10.007/16/2025PRMEPrime MedicineWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$8.00(Data available from 9/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIVAInventiva$9.95M50.52N/AN/A($1.21) per share-4.34MCRBSeres Therapeutics$126.32M1.20N/AN/A$1.61 per share10.75OLMAOlema PharmaceuticalsN/AN/AN/AN/A$7.14 per shareN/APRMEPrime Medicine$4.96M130.86N/AN/A$1.37 per share3.52Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIVAInventiva-$199.34MN/A0.00N/AN/AN/AN/AN/A9/25/2025 (Estimated)MCRBSeres Therapeutics$140K-$4.60N/AN/AN/AN/A-350.16%-67.69%11/12/2025 (Estimated)OLMAOlema Pharmaceuticals-$129.47M-$1.98N/AN/AN/AN/A-42.58%-38.65%11/11/2025 (Estimated)PRMEPrime Medicine-$198.13M-$1.56N/AN/AN/AN/A-107.87%-74.97%N/ALatest MCRB, PRME, IVA, and OLMA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/25/2025Q2 2025IVAInventiva-$0.41N/AN/AN/AN/AN/A8/11/2025Q2 2025OLMAOlema Pharmaceuticals-$0.43-$0.51-$0.08-$0.51N/AN/A8/6/2025Q2 2025MCRBSeres Therapeutics-$2.72-$2.27+$0.45-$2.27$11.75 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIVAInventivaN/AN/AN/AN/AN/AMCRBSeres TherapeuticsN/AN/AN/AN/AN/AOLMAOlema PharmaceuticalsN/AN/AN/AN/AN/APRMEPrime Medicine$1.4529.98%N/AN/A N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIVAInventivaN/A0.920.92MCRBSeres TherapeuticsN/A1.571.57OLMAOlema Pharmaceuticals0.0111.0911.09PRMEPrime MedicineN/A6.506.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIVAInventiva19.06%MCRBSeres Therapeutics59.34%OLMAOlema Pharmaceuticals91.78%PRMEPrime Medicine70.37%Insider OwnershipCompanyInsider OwnershipIVAInventiva32.00%MCRBSeres Therapeutics4.70%OLMAOlema Pharmaceuticals16.36%PRMEPrime Medicine22.74%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIVAInventiva10095.66 million65.05 millionNot OptionableMCRBSeres Therapeutics3308.75 million8.34 millionOptionableOLMAOlema Pharmaceuticals7068.63 million57.41 millionOptionablePRMEPrime Medicine234134.57 million100.38 millionOptionableMCRB, PRME, IVA, and OLMA HeadlinesRecent News About These CompaniesPrime Medicine, Inc. (NYSE:PRME) Given Average Rating of "Moderate Buy" by AnalystsSeptember 14 at 2:13 AM | marketbeat.comCathie Wood’s ARK ETF adjusts stock positions, buys PRME and TWSTSeptember 9, 2025 | investing.comPrime Medicine, Inc. (PRME) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 8, 2025 | seekingalpha.comPrime Medicine Unveils New Prime Editing AdvancementsSeptember 8, 2025 | msn.comPrime Drink Group Terminates Rights Offering and Announces Private PlacementSeptember 4, 2025 | globenewswire.comPrime Medicine, Inc. (PRME) Presents At Citi's Biopharma Back To School Conference TranscriptSeptember 2, 2025 | seekingalpha.comPrime Medicine, Inc. (PRME) Presents at Citi's Biopharma Back to School Conference - SlideshowSeptember 2, 2025 | seekingalpha.comPrime Medicine (NYSE:PRME) Stock Price Up 4.9% - Here's What HappenedAugust 27, 2025 | marketbeat.comT. Rowe Price Investment Management Inc. Has $8.25 Million Stake in Prime Medicine, Inc. $PRMEAugust 27, 2025 | marketbeat.comPrime Medicine to Participate in Upcoming Investor ConferencesAugust 26, 2025 | globenewswire.comPositive Signs As Multiple Insiders Buy Prime Medicine StockAugust 20, 2025 | uk.finance.yahoo.comPrime Medicine, Inc. (NYSE:PRME) Given Consensus Rating of "Moderate Buy" by AnalystsAugust 19, 2025 | marketbeat.comPrime Medicine, Inc.: Strong Buy Rating Backed by Promising Pipeline and Robust Financial PositionAugust 8, 2025 | tipranks.comPRME Revenue Misses by 73%August 8, 2025 | aol.comAPrime Medicine, Inc. (PRME) Reports Q2 Loss, Lags Revenue EstimatesAugust 7, 2025 | zacks.comPrime Medicine Reports Second Quarter 2025 Financial Results and Provides Business UpdatesAugust 7, 2025 | globenewswire.comPrime Medicine Holds Special Stockholder MeetingAugust 5, 2025 | tipranks.comFriday’s Insider Trades: Key Buys and Sells in US Stocks RevealedAugust 4, 2025 | investing.comPrime Medicine, Inc. (NYSE:PRME) Major Shareholder Arch Venture Partners Xii, Llc Purchases 3,030,300 SharesAugust 2, 2025 | insidertrades.comPrime Medicine Halts Sales Agreement ProspectusAugust 1, 2025 | theglobeandmail.comPrime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional SharesAugust 1, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025What NVIDIA’s Big Bet on Rival Quantinuum Means for D-Wave StockBy Nathan Reiff | September 8, 2025What to Watch for From D-Wave Now That Earnings Are DoneBy Nathan Reiff | September 2, 2025Dueling Insider Moves: Heavy Buying Here, Big Selling ThereBy Leo Miller | September 2, 2025Is Qualcomm Tesla’s Next Rival in Autonomous Driving?By Sam Quirke | September 9, 2025MCRB, PRME, IVA, and OLMA Company DescriptionsInventiva NASDAQ:IVA$5.26 -0.07 (-1.22%) As of 01:25 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.Seres Therapeutics NASDAQ:MCRB$17.31 -0.09 (-0.52%) As of 01:22 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.Olema Pharmaceuticals NASDAQ:OLMA$7.86 -0.03 (-0.38%) As of 01:26 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.Prime Medicine NYSE:PRME$4.82 +0.15 (+3.30%) As of 01:27 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Hits Record High After CEO Hock Tan AI Pay Package CrowdStrike Stock Set for Breakout as Agentic AI Demand Surges Why CoreWeave's NVIDIA Deal Creates a Deep Moat for AI Investors Resideo Technologies: Institutional Activity Signals 30% Upside This Stock Quietly Benefits From Oracle and NVIDIA’s AI Surge Rezolute Stock: FDA Fast Track Fuels 2025 Breakout Lululemon’s Sell-Off Looks Overdone: A Contrarian Case This Defense Stock Is Up 113% This Year—Is It Still a Buy? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
